Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Supergen (supg) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (106)	7/18/2001 10:24:05 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 124

GW posted a link to a news report on decitabine on the Indications_Cancer thread. Supergen has followed up today by doing a press release. Decitabine's unique mechanism of action, the regulation of methylation of DNA, allows the genes to be switched back on, so that the cells are once again sensitive to the effects of the chemotherapy. So...tumor suppressor genes are back on, or DNA repair enzymes are back on? Joe says "unique"...is that so? incyte.com interferon-resistant tumors could be made susceptible to the drug by treating them with decitabine Can a bioscientist help refine this query? google.com

To: Biomaven who wrote (106)	11/21/2001 11:26:24 AM
From: tuck	Read Replies (1) \| Respond to of 124

>>DUBLIN, Calif., Nov 21 (Reuters) - Pharmaceuticals company SuperGen Inc. (NasdaqNM:SUPG - news) said on Wednesday that U.S. regulators approved its anti-cancer drug daunorubicin. The firm, which is partly owned by Abbott Laboratories Inc.(NYSE:ABT - news), said the U.S. Food and Drug Administration approved daunorubicin as a treatment for a variety of acute leukemias. In addition to daunorubicin, SuperGen's also markets Nipent to treat hairy cell leukemia and is in clinical development for a variety of other leukemias, graft-versus-host disease and bone marrow transplantation. It also has an experimental drug called Rubitecan, which is in clinical development for treatment of pancreatic cancer, as well as ovarian, prostate, lung and stomach cancers. Shares of SuperGen traded up 28 cents, or 2 percent to $13.25 in early activity on the $13.30.<< snip Cheers, Tuck